SubHero Banner

Reblozyl® (luspatercept-aamt) – New indication

April 3, 2020 - Bristol Myers Squibb and Acceleron Pharma announced the FDA approval of Reblozyl (luspatercept-aamt), for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell (RBC) units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).

Download PDF